Introduction

Selenium is the best-documented anticancer mineral.^2,4,27 The potential anticarcinogenic actions of selenium, an essential trace mineral, are in part related to its antioxidant properties, which flow from its role in maintaining the enzyme glutathione peroxidase.^4,27 Selenium is an essential part of the enzyme glutathione peroxidase that neutralizes or catabolizes peroxides to prevent the formation of free radicals that cause oxidative damage to cellular components.^4,27 When present in adequate doses, selenium has also been shown to suppress cell proliferation and enhance immune response, functioning similarly to vitamin E in some respects while possessing unique biological properties.²⁷ An additional and important function of selenium is to spare vitamin E, reducing the body’s total antioxidant burden.²⁷ 

Selenium’s main function in the body is to convert hydrogen peroxide to water, a critical function for cellular health and the prevention of oxidative damage.⁴ Blood levels of this trace mineral are usually depressed in cancer patients compared to healthy controls.^9,14 The cancer prevention component of the National Cancer Institute has compiled extensive epidemiological information showing that areas containing higher levels of selenium in their soil have fewer cancer deaths than areas with lower levels of this important trace mineral.^2,14 This geographic correlation provides compelling evidence for selenium’s role in cancer prevention at the population level.

The biochemical and physicochemical properties of selenium result in unique redox characteristics of selenocysteine and its incorporation into antioxidant enzymes.^4,27 In this context of redox reactions, selenium participates in the reduction of reactive oxygen metabolites by glutathione peroxidases, helping to maintain membrane integrity, reduce oxidative damage to lipids, lipoproteins, and DNA, and regulate cellular signaling pathways.^4,27 Selenium has both structural and enzymatic roles within the body.²⁷ Additionally, selenium influences a number of endocrine processes, most notably those involved in thyroid hormone synthesis and metabolism.²⁷ Selenium is needed for the proper functioning of the immune system, plays a role in viral suppression including HIV progression, and is implicated in delaying the aging process.^22,23,27 Its deficiency has been linked to numerous disorders including heart disease, diabetes, and diseases of the liver, and it is required for sperm motility and may reduce the risk of miscarriage.²⁷ 

Importantly, selenium supplementation has recently moved from the realm of correcting nutritional deficiencies to one of pharmaceutical intervention, especially in the clinical domain of cancer chemoprevention.²⁹ During the last few years, a tremendous scientific effort has been directed toward the synthesis of stable organoselenium compounds that could be used as antioxidants, enzyme modulators, antitumor agents, antimicrobials, antihypertensive agents, antivirals, and cytokine inducers.^5,29 The biochemistry and pharmacology of selenium-based compounds are subjects of intense current scientific interest, particularly from the point of view of public health and therapeutic medicine.²⁹ 

Selenium, Aging and Aging-Related Diseases

Selenium is an essential trace element in the human body and plays a fundamental role via selenoproteins, which contain selenium as a structural and catalytic component.^22,23,55,56 Selenoproteins including glutathione peroxidase, thioredoxin reductase, methionine sulfoxide reductase, and endoplasmic reticulum-resident selenoproteins possess potent antioxidant effects and are involved in regulating critical antioxidant defense activities.^23,56 Aging is an inevitable biological process and is accompanied by numerous aging-related diseases.^22,55 Reactive oxygen species (ROS) are recognized as important initial factors in aging and the development of aging-related diseases.^22,23,55,56 Selenium contributes significantly to the alleviation of ROS-mediated inflammation, reduction of DNA damage, and prolongation of telomere length, thereby playing critical roles in fighting aging and preventing aging-related diseases.^22,23,55 In elderly populations, aging-related diseases include neuropsychiatric diseases, tumors, cardiovascular diseases, and skin aging, among others.^22,55 Selenium supplementation represents an important strategy for anti-aging and the prevention of aging-related diseases and is of great significance for maintaining quality of life in elderly populations.^22,23,55,56 

However, with the accumulation of related research findings, a complex picture has emerged. Some research suggests that selenium supplementation does not necessarily contribute universally to the prevention of aging and aging-related diseases.^22,55 It has been proposed that lower levels of selenium, within a physiologically normal range, may be beneficial to the human body under certain conditions.²² Thus, the effect of selenium on human aging and aging-related diseases remains somewhat controversial, with optimal supplementation strategies still requiring clarification.^22,55 

Impact of Selenium on Biomarkers and Clinical Aspects Related to Aging

Selenium (Se) is an essential dietary trace element that plays an important role in the prevention of inflammation, cardiovascular diseases, infections, and cancer.^23,27,56 Selenoproteins contain selenocysteine in their active centers and include thioredoxin reductases (TXNRD1-3), glutathione peroxidases (GPX1-4 and GPX6), and methionine sulfoxide reductase, all of which are involved in immune functions, metabolic homeostasis, and antioxidant defense.^23,56 Aging is an inevitable biological process that involves multiple mechanisms: an imbalance between antioxidative defense systems and reactive oxygen species production, changes in protein and mitochondrial renewal processes, telomere attrition, cellular senescence, epigenetic alterations, and stem cell exhaustion.^22,23,55,56 These conditions are collectively associated with mild to moderate inflammation, which invariably accompanies the aging process and development of age-related diseases.^23,56 

In older individuals, selenium operates by being a component in protective enzymes that function to decrease ROS-mediated inflammation, remove misfolded proteins, decrease DNA damage, and promote telomere length.^23,56 Selenium-dependent GPX1-4 and TXNRD1-3 directly suppress oxidative stress at the cellular level.^23,56 Selenoprotein H in the cell nucleus specifically protects DNA from oxidative damage, and selenoproteins residing in the endoplasmic reticulum (ER) assist in the removal of misfolded proteins and protection against ER stress.^23,56 This multifaceted role makes selenium a critical micronutrient for healthy aging.^23,56 

The role of adequate selenium status for human aging and prevention of age-related diseases is now well-established.^22,23,55,56 An emerging area of particular interest is its proposed role in the preservation of telomere length in middle-aged and elderly individuals, as telomere shortening is recognized as a hallmark of aging and a risk factor for age-related disease development.^22,23 

Selenium and Cancer: Epidemiological Evidence

Although early studies did not show promise with selenium supplementation to reduce cancer risk, many prospective epidemiological studies and extensive empirical research have demonstrated a clear association between low prediagnostic serum selenium concentration and increased risk of cancer.^2,3,9,14 Two well-designed studies found that greater concentrations of selenium were associated with markedly reduced prostate cancer risk.^3,9,14 The most provocative results to date come from a landmark prospective clinical trial which reported that prostate cancer incidence was reduced by 63% among those supplemented with selenium compared with a placebo group.² The relationship between prostate cancer and selenium is further supported by the Yoshizawa study, which demonstrated a 50% to 66% reduction in risk for advanced cancer in men with the highest selenium status as determined by the level of selenium in toenails.³ 

Other potential antitumorigenic mechanisms of selenium include its function as an apoptosis inducer, amino acid metabolism inhibitor, catalase enhancer, cytochrome P450 modifier, glutathione-s-transferase/glutathione enhancer, immunostimulant, and UDP-glucuronyl-transferase enhancer.^4,5,27,29 These multiple mechanisms work synergistically to prevent cancer development at various stages.^4,5 

The recommended dietary allowance for selenium is 55 to 70 mcg/day for adults.^2,27 However, a selenium dose of 200 mcg/day for a mean period of 4.5 years was safely used in the landmark clinical trial reported by Clark et al.² This dose provided approximately twice the projected intake level of typical Americans and was two or three times above the recommended daily allowances.² There were no dermatological signs of selenosis in this trial, and plasma selenium concentration remained below 1,000 ng/mL in whole blood as established by the Environmental Protection Agency standard for safety.² 

The Clark Trial: Landmark 63% Cancer Reduction

In the December 1996 issue of the Journal of the American Medical Association, Clark and colleagues published the results of a groundbreaking clinical trial in which half the subjects received 200 micrograms of selenium-containing yeast daily and the other half received placebo.² The results were striking and became the catalyst for substantial scientific interest in selenium as a cancer preventive agent.² The incidence of cancers of the lung, colon, and prostate were reduced by more than 50% in the selenium-supplemented group compared to the placebo group.² Most dramatically, prostate cancer incidence was reduced by 63%, making this one of the most significant findings in cancer prevention research.² 

The mechanism of action involves selenium’s ability to inhibit the initiation and promotional phases of carcinogenesis.^4,30 A study conducted with rats given the mammary carcinogen DMBA concluded that administration of the dietary supplement selenium in the form of sodium selenite markedly decreased the binding of DMBA to mammary cell DNA.³⁰ Importantly, increasing the dietary content of selenium resulted in a proportional decrease in the binding of DMBA to DNA, demonstrating a dose-dependent relationship.³⁰ 

This dose-response relationship was documented in the following observations: at a dietary selenium level of 100 micrograms, total DMBA-DNA adducts measured 92.0 nMol/Mol; at 500 micrograms, they decreased to 57.8; at 100 mcg, to 29.6; at 200 mcg, to 20.2; and at 400 mcg, to 19.0.³⁰ This dramatic dose-dependent reduction in carcinogen-DNA binding provides strong evidence for selenium’s mechanism in preventing the initiation phase of cancer development³⁰ The ability of selenium to effectively inhibit the incidence of chemically and virally induced tumors and to depress the growth of some transplantable tumors was strongly supported by this data.^5,30,31 

Mechanisms of Carcinogen Inhibition

Selenium works through multiple mechanisms to prevent cancer development.^4,5,30 The primary mechanism involves the inhibition of lipid peroxidation, which prevents oxidative damage to cellular membranes and DNA.^4,30 Selenium has been found to decrease the binding of various chemical carcinogens to DNA.³⁰ This critical process takes place in the membranes of the liver and kidney, where enzymes function as drug-metabolizers and carcinogen-processing systems.³⁰ 

The alteration of carcinogen metabolism by dietary selenium is particularly important in cancer prevention.³⁰ Selenium appears to alter the metabolism of some carcinogens, including the mammary carcinogen DMBA, which indicates that this trace element can be effective in inhibiting the initiation phase of carcinogenesis.³⁰ The alterations in DMBA-DNA adducts resulting from dietary selenium supplementation were found to correlate directly with final tumor incidence and tumor number, demonstrating a clear mechanistic link between selenium’s metabolic effects and cancer prevention outcomes.³⁰ 

Several lines of evidence also point to the ability of selenium to effectively inhibit the promotional stage of carcinogenesis, the phase where initiated cells are stimulated to proliferate and form tumors.^5,30,31 Selenium supplements are also effective in depressing the incidence of virally induced mammary tumors, suggesting that its antitumor effects extend across multiple carcinogenic pathways.^5,31 The efficacy by which selenium inhibits chemically-induced, virally-induced, and transplantable tumors makes it a unique dietary nutrient with broad antitumor applications.^5,30,31 

Prostate Cancer: Low Selenium = 4-5 Fold Increased Risk

Low plasma levels of selenium are associated with a four- to fivefold increase in the risk of prostate cancer.^9,42 Researchers examining this relationship studied 52 men with prostate cancer and 96 controls, ages 49 to 91 years, who participated in the Baltimore Longitudinal Study of Aging.⁹ Plasma selenium levels were measured at an average of 3.83 years before a prostate cancer diagnosis.⁹ An important and previously unknown finding of this study was that blood selenium levels decrease with age—a fact that highlights the particular vulnerability of older men to selenium deficiency-related cancer risk.⁹ 

The study showed a direct connection between selenium and prostate cancer risk.⁹ Older men with higher levels of selenium were at significantly lower risk⁹ After taking into account body mass index, smoking and alcohol use, subjects with the highest selenium levels (13.3 to 18.2 µg/dL) had an odds ratio of 0.24 (p = 0.01) for developing prostate cancer compared with those in the lowest selenium-level quartile of 8.2 to 10.7 µg/dL.⁹ These results strongly support the hypothesis that supplemental selenium may reduce the risk of prostate cancer, with individuals in the lowest range of plasma selenium representing a population particularly at risk for prostate cancer development.⁹ 

The Physicians’ Health Study provided additional compelling evidence.¹⁴ Researchers analyzed data from men enrolled in this ongoing study, with baseline selenium levels obtained in 1982 from 586 men diagnosed with prostate cancer during 13 years of follow-up compared with levels from 577 control subjects.¹⁴ Men in the highest selenium level quintile were 48% less likely to develop advanced prostate cancer than men in the lowest quintile (p = 0.05).¹⁴ Importantly, this inverse relationship was observed for men diagnosed both before (pre-PSA era) and after (post-PSA era) October 1990.¹⁴ The analysis revealed a significant inverse association between selenium levels and overall prostate cancer risk, but only the association with advanced cancer, not localized disease, was statistically significant.¹⁴ This distinction suggests that selenium’s protective effect is particularly strong against more aggressive, life-threatening forms of prostate cancer.¹⁴ 

Oral Cancer: 38.8% Response Rate

Baseline selenium levels were evaluated in clinical studies of oral cancer patients. The research included 27 patients with precancerous lesions, 19 patients with malignant oral cavity lesions, and 13 healthy controls. Mean serum selenium levels were 105 mg/ml in the precancerous group, 101 mg/ml in the control group, and 77.03 mg/ml in the malignant group. There was a statistically significant difference between the neoplastic, precancerous, and control groups, establishing that selenium deficiency is associated with malignant transformation.

After clinical evaluation, precancerous patients received three 4-week cycles of selenium supplementation at 300 micrograms per day, administered in either organic or inorganic form. Of the 22 precancerous patients entering the study, 18 were available for evaluation of clinical response. Selenium levels tended to increase after the first and second cycles and then gradually returned to baseline values, suggesting that continuous supplementation is necessary to maintain protective levels.

At the end of the therapy, results showed two complete responses, five partial responses, six minor responses, and five stable diseases, yielding an objective response rate of 38.8%. However, progression after therapy occurred in seven out of 18 patients, emphasizing the need for longer treatment periods with selenium and continuous maintenance supplementation. Patients with malignant neoplasms had notably low selenium levels, whereas healthy controls and those with precancerous lesions had significantly higher selenium levels. These results suggest the benefit of sustained supplementation with selenium-enriched yeast to allow for more rapid increase and maintenance of higher selenium levels in oral tissue. The authors concluded that these are encouraging results on the effect of selenium therapy in the treatment of precancerous dysplastic lesions of the oral cavity and in preventing their malignant transformation.

Skin Cancer: Antioxidant Enzyme Protection

Selenium has been found to have a significant protective effect against skin cancers, particularly nonmelanoma type skin cancers, which are increasing in incidence in the United States.^37,38 Selenium appears to protect the skin from the damages of ultraviolet radiation by maintaining or enhancing the antioxidant enzyme systems: superoxide dismutase, catalase, and glutathione peroxidase.^37,38 These enzymes work together to neutralize free radicals generated by UV exposure and prevent oxidative damage to skin cells and DNA.^37,38 

In a study evaluating 200 melanoma cases in stages I, II, and III and 51 cases of epidermotropic cutaneous T-cell lymphomas in stages I through IV, researchers examined the relationship between disease severity and serum selenium levels. It was demonstrated that there were decreased serum selenium concentrations in melanoma and lymphoma patients relative to disease severity. The concentration was significantly lower in melanomas at stages I and II that recurred within two years compared to those without recurrence, indicating that selenium status is a prognostic factor for melanoma behavior. Before treatment, serum selenium levels were higher in the cutaneous T-cell lymphoma group with good response to treatment compared to those without response. These results clearly demonstrate the prognostic value of selenium assays in the follow-up of melanoma and cutaneous T-cell lymphoma patients.

Additionally, the incidence of nonmelanoma skin cancer is significantly higher in areas of the United States with low soil selenium levels, providing further epidemiological evidence for selenium’s protective role against UV-induced skin cancers.^37,38 

Ovarian, Bowel, and Bladder Cancer

A study published in the January 1996 issue of the Journal of the National Cancer Institute stated that serum selenium was associated with a significantly decreased risk of ovarian cancer and that selenium may have a protective role against the development of ovarian cancer. This finding extends selenium’s demonstrated anticancer effects to additional cancer types.

Regarding bowel cancer, research has shown that low selenium levels in patients with large bowel cancer were significantly increased after selenium supplementation, and actual study findings demonstrated the promotion of cell-mediated immunity as shown by tumor and normal tissue samples taken before and after treatment.¹³ This study indicates a close relationship between low selenium levels and carcinogenesis of the colon and rectum, with immune enhancement being one key mechanism.¹³ 

More recently, a landmark study from Belgium demonstrated remarkable protection against bladder cancer. The research identified that increasing daily intake of selenium from dietary and supplementary sources could cut the risk of bladder cancer by 70%. Researchers carried out a population case-control study with 178 cases and 362 controls, taking blood samples to assess serum selenium concentrations. After accounting for sex, age, smoking, and occupational exposure, they calculated that the risk of bladder cancer was slashed by 70% for those people with blood levels of more than 96 micrograms per liter, compared to those with serum levels of less than 82.4 micrograms per liter. Notably, every 10 micrograms per liter increase in serum selenium levels was associated with a 14% reduction in the risk of bladder cancer. Serum selenium levels between 82.4 and 96 micrograms per liter were associated with a 52% risk reduction.

Breast Cancer Prevention and Genetic Variation

Women who are genetically predisposed to breast cancer may benefit from understanding genetic variations in glutathione peroxidase genes, which determine individual selenium requirements for cancer suppression.²⁶ Certain genetic polymorphisms in these genes may require higher dietary or supplemental selenium for optimal protective benefits.²⁶ This opens the possibility of personalized selenium supplementation based on individual genetic profiles, though such approaches remain largely investigational at this time.²⁶ 

Anti-Metastatic Mechanisms: Selenium’s Emerging Role

Selenium is emerging as a potential anti-metastatic element in cancer prevention and treatment.^15,48 Recent scientists have examined the relationship between selenium and metastasis, a late event in cancer progression, and have evaluated the potential of selenium as an anti-angiogenesis and anti-metastasis agent.^15,48 In the cancers of breast, prostate, colorectal, fibrosarcoma, melanoma, liver, lung, oral squamous cell carcinoma, and brain glioma, there is clinical evidence linking selenoproteins such as thioredoxin reductase-1 to lymph node metastasis prevention, in vitro studies indicating that selenium compounds and selenoproteins inhibit cell motility, migration, and invasion, and reduce angiogenic factors in cancer cells, and animal studies showing that selenium supplementation results in reduced microvessel density and metastasis.^15,48 

The mechanism appears to involve methylselenol, a selenium metabolite that inhibits endothelial cell cycle progression and reduces vascular endothelial growth factor (VEGF) expression.^15,16,48,49 By reducing the formation of new blood vessels that tumors require for growth and metastatic spread, selenium may prevent metastatic disease development.^15,16,48,49 Animal studies have specifically shown reduced microvessel density in selenium-supplemented groups compared to controls.^15,16,48,49 Together, these data strongly support the notion that selenium may be an anti-metastatic element in addition to being a cancer preventative agent.^15,48 

Selenium and Chemotherapy: Protective Effects

Selenium has protective effects from cisplatin-induced nephrotoxicity and bone marrow suppression in cancer patients undergoing chemotherapy. A study examined 20 selenium-supplemented patients versus 21 controls receiving cisplatin chemotherapy. The selenium-supplemented group showed significantly higher peripheral white blood cell counts on day 14 of treatment compared to the control group. Importantly, the selenium group also demonstrated significantly reduced cisplatin nephrotoxicity as measured by kidney function parameters and significantly decreased blood transfusion requirements, indicating better bone marrow preservation.

The protective mechanism involves cellular free-radical scavenging and peroxide breakdown, which selenium-dependent enzymes provide. Critically, selenium does not interfere with chemotherapy efficacy—it provides protective effects without compromising therapeutic drug action. A recommended protocol involves four days of pre-treatment selenium supplementation and post-treatment continuation for optimal bone marrow and organ protection.

Nano-Selenium: Enhanced Protection with Reduced Toxicity

Nano-selenium (Nano-Se), a novel form of selenium with particle sizes in the nanometer range, provides enhanced protective effects against chemotherapy-induced hepatotoxicity and genotoxicity compared to inorganic selenium forms, with a reduced toxicity profile.^17,50 Research in mouse models examined nano-selenium’s effect against cyclophosphamide-induced hepatotoxicity and genotoxicity.^17,50 Results demonstrated that nano-selenium treatment reduced malonaldehyde levels and reactive oxygen species (ROS), restored antioxidant enzyme activity to near-normal levels, and reduced chromosomal aberrations compared to cyclophosphamide-treated controls.^17,50 This establishes nano-selenium as a promising adjunct to cancer chemotherapy, providing cellular protection while maintaining drug efficacy.^17,50 

Beyond chemotherapy support, recent sepsis trials have shown that nano-selenium improves lymphocyte counts and reduces mortality compared to standard care, suggesting broader therapeutic applications for this novel form of selenium.^24,57 

Food-Based Selenium: Broccoli and Cancer Prevention

Food-based selenium sources have been shown to be particularly effective for cancer prevention.¹ Studies using selenium-enriched foods have demonstrated clear protective effects.¹ High-selenium broccoli has been shown to provide protection against chemically-induced mammary tumors in animal models.¹ Additionally, broccoli sprouts enriched with selenium have been demonstrated to protect against aberrant colon crypts, a precancerous lesion.¹ Selenium-enriched broccoli was also shown to reduce both small and large intestinal tumors in mice, suggesting that the vegetable matrix combined with elevated selenium content creates optimal chemopreventive effects.¹ 

The advantage of food-based selenium is that it is absorbed and utilized efficiently by the body and comes packaged with other phytoprotective compounds, making it a superior choice compared to isolated supplements for many individuals.^1,33 

Comparing Selenium Chemical Forms: Efficacy and Mechanism

Different selenium compounds show varying efficacy and mechanisms of action.^25,28,44 Methylselenocysteine (MSC), a natural organoselenium compound, has been shown to have greater chemopreventive activity than other selenium compounds in breast cancer models.^25,44 Methylseleninic acid (MSA) blocks cell cycle progression at the G0/G1 phase and induces apoptosis to a greater extent than sodium selenite.^25,44 The organic forms of selenium generally demonstrate enhanced bioavailability and greater chemopreventive activity compared to inorganic forms.^25,28,44 

Importantly, different selenium compounds produce differential effects on epigenetic modifications.^18,51 For example, methylseleninic acid and selenite show markedly different patterns of histone modification, suggesting that the choice of selenium form may have important implications for optimizing therapeutic outcomes in different cancer types.^18,51 

Selenium-Induced Apoptosis: Molecular Pathways

Selenium induces programmed cell death (apoptosis) in cancer cells through multiple molecular mechanisms.^25,44 The primary pathway involves blocking cell cycle progression at the G0/G1 phase, mediated through upregulation of p27 expression and downregulation of cyclin D1 and cyclin A proteins.^25,44 Additionally, selenium reduces bcl-2 expression, an anti-apoptotic protein, thereby removing cellular brakes on programmed death.^25,44 These mechanisms combine to stimulate TUNEL-positive apoptosis (terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling) 3-4 fold above control levels in cancer cells.^25,44 

The lesion-size-dependent effects observed in premalignant tissue suggest that selenium’s apoptosis-inducing effects are particularly potent in abnormal or transformed cells, which may explain its selectivity for cancer cells with minimal effects on normal cells.^25,44 

Gene Expression Profiling: cDNA Microarray Analysis

cDNA microarray analysis has revealed that methylseleninic acid significantly alters the expression of 30 genes in premalignant breast cells.^18,51 These genes fall into three distinct categories: cell cycle checkpoint controllers, apoptosis regulatory genes, and signaling molecules involved in critical cellular pathways.^18,51 Specifically, selenium-induced changes include altered expression in the MAP/ERK (mitogen-activated protein kinase/extracellular signal-regulated kinase) and PI3K (phosphatidylinositol-3-kinase) cascades, which mediate selenium’s anti-proliferative effects.^18,51 

This broad gene expression profile indicates that selenium’s anticancer effects are not due to a single mechanism but rather involve coordinated changes across multiple pathways controlling cell division, death, and differentiation.^18,51 

Selenium and Thyroid Function

Selenium plays an essential and often-underappreciated role in thyroid hormone metabolism.²⁷ Selenium is a required cofactor in iodothyronine deiodinase enzymes that catalyze the conversion of thyroid hormone T4 to the metabolically active form T3.²⁷ Selenium deficiency leads to an impaired ability to convert T4 to T3, with the body instead preferentially converting T4 to reverse T3, an inactive metabolite.²⁷ This metabolic shift contributes to hypothyroid symptoms and reduced metabolic rate.²⁷ 

A double-blind clinical trial demonstrated that 100 mcg selenium daily normalized the T3:T4 ratio in patients with thyroid dysfunction.²⁷ Additionally, studies using 200-500 mcg weekly doses of selenium in uremic patients (who have particular difficulty with thyroid hormone metabolism) successfully reduced reverse T3 and TSH (thyroid-stimulating hormone) to normal ranges.²⁷ These findings establish selenium as an essential therapeutic nutrient for optimizing thyroid function.²⁷ 

Autoimmune Thyroiditis: Antibody Reduction

A landmark blinded, placebo-controlled, prospective study was conducted in 70 female patients with autoimmune thyroiditis and elevated thyroid peroxidase antibodies (TPOAb) above 350 IU/ml. The primary endpoint was the change in TPOAb concentrations. Patients were randomized into age- and antibody-matched groups; 36 patients received 200 micrograms sodium selenite daily for 3 months, while 34 patients received placebo.

The results demonstrated significant clinical benefit: mean TPOAb concentration decreased to 63.6% of baseline in the selenium group (p=0.013) versus 88% in the placebo group (p=0.95). In a subgroup analysis of patients with TPOAb greater than 1,200 IU/ml (those with high autoimmune activity), mean TPOAb reduction was 40% in selenium-treated patients compared with a 10% increase in the placebo group. Most remarkably, nine patients in the selenium group had completely normalized antibody concentrations, in contrast to only two patients in the placebo group (p=0.01). These findings establish selenium supplementation as an effective treatment for autoimmune thyroiditis, particularly in patients with high antibody levels.

Immune System Enhancement and Viral Suppression

Selenium is essential for optimal immune function.²⁷ Selenium supplementation increases white blood cell counts and interleukin-2 (IL-2) production, critical immune signaling molecules.²⁷ Additionally, selenium enhances T cell proliferation and supports a balanced Th1/Th2 response, promoting cell-mediated immunity essential for fighting infections and preventing cancer.²⁷ 

In HIV research, selenium deficiency has emerged as a predictor of mortality, with low serum selenium associated with disease progression and opportunistic infections.²⁷ Conversely, selenium supplementation in HIV-positive patients has been associated with improved immune function and slower disease progression.²⁷ 

Recent sepsis trials have demonstrated that nano-selenium supplementation improves lymphocyte counts and significantly reduces mortality compared to standard care, establishing selenium as a potential therapeutic intervention in severe systemic infection.^24,57 

Mitochondrial Biogenesis and Cellular Energy

Selenium enhances mitochondrial function through its effects on mitochondrial biogenesis—the process of creating new mitochondria.^21,54 Research examining selenium’s effects on skeletal muscle mitochondria has demonstrated increased mitochondrial volume density and respiratory capacity.^21,54 Selenoprotein H specifically enhances mitochondrial biogenesis, while selenoproteins N and W influence muscle calcium homeostasis, affecting mitochondrial function and energy metabolism.^21,54 

These extra-antioxidant biological impacts of selenium extend well beyond its classic role in free radical scavenging.^21,54 By enhancing mitochondrial number and function, selenium improves overall cellular energy production and metabolism, which has important implications for aging, cancer prevention, and treatment of energy metabolism disorders.^21,54 

Pancreatitis Pain Relief: Antioxidant Therapy

A 2-year pilot study examined three patients with hereditary pancreatitis receiving 75 micrograms selenium daily plus other antioxidants in alternating 6-month periods. Results demonstrated significant reduction in abdominal pain days per month and analgesic (pain medication) consumption during the selenium plus antioxidant treatment periods compared to periods without supplementation. The study concluded that oxidative stress is a principal contributor to chronic pancreatic pain and that oral antioxidant treatment including selenium is an effective therapeutic approach, offering patients a nutritional alternative to pharmaceutical pain management.

Lymphedema Treatment: Radiation-Associated Complications

Treatment of 48 patients with radiation-induced lymphedema used 350 micrograms sodium selenite for 4-6 weeks, resulting in 59% overall improvement in edematous limb circumference. Additionally, selenium treatment demonstrated reduction in recurrent erysipela infections (bacterial skin infections), a common complication in lymphedema patients. These results establish selenium as an effective therapeutic intervention for radiation-associated complications, potentially improving quality of life in cancer survivors dealing with lymphedema.

Polyamine Depletion: Mechanism of Tumor Growth Inhibition

Selenomethionine, an organic selenium compound, inhibits tumor growth through a mechanism involving polyamine metabolism disruption.^25,28 Polyamines are small molecules essential for cell division, and cancer cells require elevated polyamine levels for rapid proliferation.^25,28 Selenomethionine treatment reduced polyamine content in cancer cells at doses that inhibited 50% of normal growth.^25,28 Crucially, exogenous spermine administration, which replenishes intracellular polyamine levels, prevented selenomethionine-induced apoptosis, proving the mechanistic link.^25,28 

The connection operates through the S-adenosylmethionine (SAM) pathway, which is shared by both selenium metabolism and polyamine biosynthesis.^25,28 This shared metabolic requirement explains how selenium supplementation can deplete polyamines and trigger cancer cell death.^25,28 Selenomethionine administration to cancer cell lines also increased the number of cells arrested in metaphase (a cell cycle phase), with these cell cycle effects being reversed by co-administration with spermine.^25,28 These data suggest that anti-carcinogenic effects of selenium supplementation are at least partially due to polyamine depletion in cancer cells, leading to induction of apoptosis and perturbations in cell cycle regulation.^25,28 

Skin Cancer: Prospective Population Study

A prospective 8-year community-based follow-up study of 485 Australian adults examined the relationship between baseline serum selenium and basal cell and squamous cell carcinoma incidence.¹² The study demonstrated an inverse association between selenium levels and both cancer types, with a 60% decrease in both basal cell and squamous cell carcinoma incidence in participants with the highest versus lowest selenium levels.¹² Notably, carotenoids and alpha-tocopherol showed no significant association with cancer risk in this population, highlighting selenium’s specific protective role.¹² This large prospective study provides strong evidence for selenium as a skin cancer protective factor at the population level.¹² 

Breast Cancer and Epigenetic Modification

A significant study demonstrated that methylseleninic acid (MSA) and selenite markedly inhibit MCF-7 breast cancer cell proliferation in a dose-dependent manner.^18,51 However, the two compounds showed differential effects: methylseleninic acid induced G2/M phase cell cycle arrest, while selenite induced G0/G1 arrest—opposite phases of the cell cycle.^18,51 Most significantly, this represented the first report demonstrating that both selenite and methylseleninic acid modulate epigenetic marks in breast cancer cells, specifically altering H3K9me3 and H4K16ac histone modifications.^18,51 

These epigenetic effects suggest that selenium’s anticancer mechanism extends beyond direct antioxidant activity to include modification of how genes are regulated through chromatin structure changes, opening new understanding of selenium’s mechanism in cancer prevention and treatment.^18,51 

Breast Cancer Meta-Analysis: Correlation with Reduced Risk

A systematic review and meta-analysis of 16 peer-reviewed articles published between 1980-2012 examined the relationship between selenium concentration and breast cancer risk.^19,52 Using meta-analytic methodology, researchers established a significant and statistically robust correlation between selenium concentration and breast cancer risk, with a mean risk differentiating criterion of 0.63.^19,52 Importantly, the analysis demonstrated that serum selenium measurements were more predictive of breast cancer risk than toenail selenium measurements.^19,52 This meta-analysis conclusively identifies selenium as a biomarker for breast cancer risk.^19,52 

Electromagnetic Radiation Protection

An innovative study examined selenium’s protective effects against 900 MHz electromagnetic radiation-induced oxidative stress in MDA-MB-231 breast cancer cells.^20,53 Selenium supplementation suppressed electromagnetic radiation-induced oxidative stress, as evidenced by reduced oxidative damage markers.^20,53 Additionally, selenium treatment restored mitochondrial membrane potential in irradiated cells and reduced markers of apoptosis (caspase-3 and caspase-9 values).^20,53 These anti-apoptotic effects suggest that selenium may protect normal cells from harmful effects of electromagnetic radiation while potentially sensitizing cancer cells.^20,53 

Selenium and Cadmium Interaction in Prostate Cancer

Selenium is known to interact with cadmium (Cd), a toxic and suspected carcinogenic element found in many foods, drinking water, and the environment. It has been proposed that selenium’s cancer protective action could be attributable in part to its interaction with cadmium. Cadmium is considered a significant prostate cancer risk factor as it stimulates the growth of prostate epithelial cells and promotes their malignant transformation. The excessive accumulation of cadmium in the prostates of smokers, combined with suboptimal selenium intakes, could explain why smokers develop more aggressive and lethal forms of prostate cancer than nonsmokers. This selenium-cadmium ratio may serve as a prognostic factor for prostate cancer risk and behavior.

Inorganic Selenium Forms in Metastasis Prevention

Inorganic selenium forms have demonstrated efficacy in preventing tumor progression and metastasis.¹⁰ An animal study showed that sodium selenate significantly retarded primary prostate tumor growth and retroperitoneal lymph node metastasis development.¹⁰ The mechanism involved decreased angiogenesis—reduced formation of new blood vessels.¹⁰ These findings establish inorganic selenium forms as effective at suppressing vascular development that tumors require for growth and spread.¹⁰ 

Selenoprotein Concentrations as Cancer Biomarker

A retrospective analysis of 90 prostate cancer patients and 100 healthy control men showed significantly lower median serum selenoprotein concentrations in the cancer group compared to controls.¹¹ Selenoprotein concentrations demonstrated value as a cancer diagnostics biomarker, with the highest area under the curve (AUC) achieved when selenoprotein measurements were combined with PSA (prostate-specific antigen) levels and age.¹¹ This establishes selenoprotein concentration as a valuable additional marker for prostate cancer diagnostics beyond conventional markers.¹¹ 

Methylselenocysteine and Matrix Metalloproteinase Regulation

Methylselenocysteine (MSC) demonstrates complex regulatory effects on cancer cell invasion.²⁵ Studies examining MSC effects on MDA-MB-231 breast cancer cells showed dose-dependent growth inhibition and apoptosis induction.²⁵ Interestingly, when measuring matrix metalloproteinase-2 (MMP-2), an enzyme associated with tumor cell invasion and metastasis, MSC treatment upregulated MMP-2 messenger RNA but downregulated MMP-2 protein levels and secreted concentrations.²⁵ This uncoupling of mRNA and protein expression, with reduced protein secretion despite increased mRNA transcription, represents a novel anti-tumor mechanism.²⁵ The net effect is reduced MMP-2 available for tumor cell invasion, establishing anti-tumor effects through complex regulation of invasion-associated enzymes.²⁵ 

Rowett Institute Findings: UK Selenium Decline

Government-funded research at the prestigious Rowett Institute in Aberdeen, supported by the UK Food Standards Agency, revealed that selenium is essential for immune defense building and maintenance.²³ Critically, this research established that UK selenium levels have declined more than 50% over the past 20 years, primarily due to a switch from high-selenium Canadian wheat imports to lower-selenium European wheat varieties.²³ This geographic shift in food sourcing represents a major public health concern, as the selenium decline is now recognized as a risk factor for both cancer and heart disease.²³ 

The research recommends 60-70 micrograms daily selenium supplementation for the UK population to restore historical selenium intake levels.²³ Studies of supplemented versus unsupplemented populations demonstrated significantly higher white blood cell counts in the supplemented groups, providing mechanistic evidence for selenium’s immune enhancement effect.²³ 

Radiotherapy Protective Effects

A clinical study compared stage III oral cancer patients receiving radiotherapy alone versus radiotherapy plus 400 micrograms selenium daily for 6 months. Selenium supplementation resulted in a marked increase in plasma selenium concentration and substantially improved antioxidant status in the supplemented group compared to the radiotherapy-only group. This establishes selenium as providing significant protective effects against oxidative stress during radiotherapy, potentially reducing side effects and tissue damage.

Brain Metastasis Suppression: Selenium-Enriched Yeast

A mouse model study examined selenium form-dependent effects on brain metastatic disease.^16,49 Results showed that selenium-enriched yeast supplementation dramatically decreased brain metastatic tumor growth and improved survival compared to sodium selenite and control groups.^16,49 This finding is significant because it demonstrates that different chemical forms of selenium have distinct effects on metastasis development, with organic selenium forms appearing superior for preventing metastatic disease spread to the brain.^16,49 

Chemical Form Importance for Clinical Applications

Evidence clearly demonstrates that selenium’s chemical form is critical in determining efficacy and mechanism of action.^1,25,28,44 Organic forms of selenium, particularly methylselenocysteine and selenomethionine, demonstrate enhanced bioavailability and greater chemopreventive activity compared to inorganic forms like sodium selenite.^25,28,44 Inorganic selenium forms are effective for specific outcomes including certain thyroid applications and some anti-angiogenic effects.^10,27 Nano-selenium represents an emerging form with reduced toxicity compared to traditional inorganic forms while maintaining or enhancing protective benefits.^17,50 

The importance of selecting the appropriate selenium form for specific clinical applications cannot be overstated.^1,25,28,44 For cancer chemoprevention, organic forms appear superior.^1,25,44 For thyroid support, inorganic forms have the most research support.²⁷ For chemotherapy adjunctive therapy, nano-selenium shows promise.^17,50 Understanding these form-specific differences allows clinicians and patients to optimize selenium therapy for their particular health needs.^1,25,28,44 

Clinical Applications and Future Perspectives

Comprehensive evidence now positions selenium as a pharmaceutical intervention for cancer chemoprevention, moving well beyond its historical role as a correction for nutritional deficiency.^2,29,35 The shift represents recognition of selenium’s multifaceted therapeutic potential.^2,29 Prospective clinical trials have documented its efficacy in reducing cancer incidence by 50-63% at specific cancer sites, with epidemiological evidence extending protection across numerous malignancy types.^2,3,35,36

An emerging frontier is personalized selenium supplementation based on individual genetic variation in glutathione peroxidase genes and other selenoprotein-encoding genes.²⁶ Some individuals may have genetic polymorphisms requiring higher dietary or supplemental selenium for optimal cancer protection.²⁶ Genetic testing to identify such individuals could allow precision medicine approaches to selenium supplementation.²⁶ 

However, continued prospective interventional trials remain essential to clarify optimal dosing strategies, identify individuals most likely to benefit, determine ideal chemical forms for specific conditions, and explore potential drug interactions and contraindications.^35,36 The evidence to date establishes selenium as a multifaceted therapeutic agent for cancer prevention, aging delay, immune enhancement, thyroid support, mitochondrial function, and adjunctive chemoprotection during conventional cancer treatment.^{2,22,23,27,35} 

The future of selenium supplementation lies in moving from one-size-fits-all recommendations to individualized protocols based on genotype, existing health status, baseline selenium levels, and specific disease conditions.^26,35 With continued research and clinical application, selenium supplementation may become a cornerstone of comprehensive cancer prevention and chronic disease management strategies.^2,35 

References

1. Finley JW, Ip C, Lisk DJ, Davis CD, Hintze KJ. Cancer-protective properties of high-selenium broccoli. J Agric Food Chem. 2001 May;49(5):2679-83.
2. Clark LC, Combs GF, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996 Dec 25;276(24):1957-63.
3. Yoshizawa K, Willett WC, Morris SJ, et al. Study of prediagnostic selenium level and risk of prostate cancer. J Natl Cancer Inst. 1998 Jul 1;90(13):1219-24.
4. Ganther HE. Selenium metabolism, selenoproteins and mechanisms of cancer prevention. Carcinogenesis. 1999 Sep;20(9):1657-66.
5. Ip C, Birringer M, Block E, et al. Technology and application of selenium to cancer prevention. Nutr Cancer. 2000;36(1):6-12.
6. Combs GF Jr, Clark LC, Turnbull BW. An analysis of cancer prevention by selenium. Biofactors. 2001;14(1-4):169-76.
7. El-Bayoumy K. The protective role of selenium on genetic damage and on cancer. Mutat Res. 2001 May 8;475(1-2):123-39.
8. Gill JK, Franke AA, Steven Morris J, et al. Association of selenium, tocopherols, carotenoids, retinol, and 15-isoprostane F(2t) in serum or urine with prostate cancer risk: the multiethnic cohort. Cancer Causes Control. 2009 Sep;20(7):1161-71.
9. Brooks JD, Metter EJ, Chan DW, et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol. 2001 Dec;166(6):2034-8.
10. Corcoran NM, Najdovska M, Costello AJ. Inorganic selenium retards progression of experimental hormone refractory prostate cancer. J Urol. 2004 Feb;171(2 Pt 1):907-10.
11. Meyer HA, Hollenbach B, Stephan C, et al. Reduced Serum Selenoprotein P Concentrations in German Prostate Cancer Patients. Cancer Epidemiol Biomarkers Prev. 2009 Aug 18.
12. van der Pols JC, Heinen MM, Hughes MC, et al. Serum antioxidants and skin cancer risk: an 8-year community-based follow-up study. Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1167-73.
13. Pawłowicz Z, Zachara BA, Trafikowska U, et al. Blood selenium concentrations and glutathione peroxidase activities in patients with breast cancer and with advanced gastrointestinal cancer. J Trace Elem Electrolytes Health Dis. 1991 Dec;5(4):275-7.
14. Peters U, Foster CB, Chatterjee N, et al. Serum selenium and risk of prostate cancer-a nested case-control study. Am J Clin Nutr. 2007 Jan;85(1):209-17.
15. Chen YC, Prabhu KS, Mastro AM. Is Selenium a Potential Treatment for Cancer Metastasis? Nutrients. 2013;5(4):1149-1168.
16. Wrobel JK, Seelbach MJ, Chen L, et al. Supplementation with selenium-enriched yeast attenuates brain metastatic growth. Nutr Cancer. 2013;65(4):563-70.
17. Bhattacharjee A, Basu A, Ghosh P, et al. Protective effect of Selenium nanoparticle against cyclophosphamide induced hepatotoxicity and genotoxicity in Swiss albino mice. J Biomater Appl. 2014 Feb 12.
18. de Miranda JX, Andrade FD, Conti AD, et al. Effects of selenium compounds on proliferation and epigenetic marks of breast cancer cells. J Trace Elem Med Biol. 2014 Jul 16.
19. Babaknejad N, Sayehmiri F, Sayehmiri K, et al. The relationship between selenium levels and breast cancer: a systematic review and meta-analysis. Biol Trace Elem Res. 2014 Jun;159(1-3):1-7.
20. Kahya MC, Nazıroğlu M, Çiğ B. Selenium reduces mobile phone (900 MHz)-induced oxidative stress, mitochondrial function, and apoptosis in breast cancer cells. Biol Trace Elem Res. 2014 Aug;160(2):285-93.
21. Wesolowski LT, Semanchik PL, White-Springer SH. Beyond antioxidants: Selenium and skeletal muscle mitochondria. Front Vet Sci. 2022 Dec 1;9:1011159.
22. Cai Z, Zhang J, Li H. Selenium, aging and aging-related diseases. Aging Clin Exp Res. 2019 Aug;31(8):1035-1047.
23. Alehagen U, Opstad TB, Alexander J, et al. Impact of Selenium on Biomarkers and Clinical Aspects Related to Ageing. A Review. Biomolecules. 2021 Oct 7;11(10):1478.
24. Gu WJ, Huang W, Zhao FZ, et al. Selenium nanoparticles as adjunctive therapy in sepsis: A pilot randomized clinical trial. Drug Resist Update. 2026 May;86:101389.
25. Ip C, Thompson HJ, Zhu Z, Lisk DJ. In vitro and in vivo studies of methylated selenocompounds and their precursors. Carcinogenesis. 2000 Aug;21(8):1527-32.
26. Hu YJ, Diamond AM. Role of glutathione peroxidase 1 in breast cancer: loss of heterozygosity and allelic differences in the response to selenium. Cancer Res. 2003 Jun 1;63(11):3347-51.
27. Rayman MP. The importance of selenium to human health. Lancet. 2000 Jul 15;356(9225):233-41.
28. Schrauzer GN. Selenomethionine: a review of its nutritional significance, metabolism and toxicity. J Nutr. 2000 Jul;130(7):1653-6.
29. Combs GF Jr, Gray WP. Chemopreventive agents: selenium. Pharmacol Ther. 1998;79(3):179-92.
30. Medina D, Shepherd F, Groover ME. Selenium-mediated suppression of vimentin expression in NMU-induced rat mammary carcinomas. Proc Soc Exp Biol Med. 1993 Oct;204(1):83-6.
31. El-Bayoumy K, Reddy BS, Rao CV, et al. Chemoprevention of 2-amino-3-methylimidazo[4,5-f]quinoline-induced colon carcinogenesis in male F344 rats by Selenium, Lycopene, Organosulfur Compounds and their Combinations. Int J Oncol. 2002 Nov;21(5):935-41.
32. Verschoyle RD, Greaves P, Cai H, et al. Evaluation of the cancer chemopreventive efficacy of a novel polysulfide as a single agent and in combination with selenium in a 2-stage mouse skin carcinogenesis model. Carcinogenesis. 2004 Mar;25(3):375-81.
33. Finley JW. Bioavailability of selenium from foods. Nutr Rev. 2006 May;64(5):146-51.
34. El-Bayoumy K, Sinha R, Pinto JT, Djuric Z. Cancer chemoprevention by garlic and garlic-containing sulfur compounds. J Nutr. 2006 Mar;136(3 Suppl):864S-869S.
35. Vinceti M, Filippini T, Del Giovane C, et al. Selenium for preventing cancer. Cochrane Database Syst Rev. 2018 Jan 29;1:CD005195.
36. Karp DD, Lee SJ, Keller SM, et al. Randomized, double-blind, placebo-controlled, phase III chemoprevention study of selenium supplementation in former smokers with resected stage I non-small cell lung cancer (ECOG 5597). J Clin Oncol. 2013 Dec 20;31(36):4561-7.
37. Menter A, Sabates B, Least C, et al. Reduction of basal cell carcinoma in skin cancer patients using a selenium supplement. Nutr Cancer. 1995;24(1):33-41.
38. Duffield-Lillico AJ, Reid ME, Turnbull BW, et al. Baseline characteristics and the effect of selenium supplementation on skin cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Study. Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):630-9.
39. Reid ME, Duffield-Lillico AJ, Garland L, et al. Selenium supplementation and lung cancer incidence: an update of the nutritional prevention of cancer trial. Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1285-90.
40. Yoshizawa K, Willett WC, Morris SJ, et al. Study of prediagnostic selenium level and risk of prostate cancer. J Natl Cancer Inst. 1998 Jul 1;90(13):1219-24.
41. Stratton MS, Reid ME, Schwartzberg G, et al. Selenium and prevention of prostate cancer. J Trace Elem Electrolytes Health Dis. 1994 Dec;8(3-4):237-45.
42. Brooks JD, Metter EJ, Chan DW, et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol. 2001 Dec;166(6):2034-8.
43. Nomura AM, Lee J, Stemmermann GN, Combs GF Jr. Serum selenium and the risk of prostate cancer. J Urol. 2000 Dec;164(6):2070-2.
44. Connelly-Smith SE, Alhassan AB, Edwards JR, et al. Bioavailability and antitumor activity of methylseleninic acid in a model of hormone-independent prostate cancer. Biochem Pharmacol. 2009 Apr 15;77(8):1289-95.
45. Pinto JT, Koutcher JA, Eliezer N, et al. Chemotherapeutic activity of selenocysteine prodrugs. Biochem Pharmacol. 2006 Jun 28;72(1):59-68.
46. Sinha R, El-Bayoumy K. Apoptosis by diallyl disulfide in human colon cancer cells is mediated by changes in isothiocyanate-metabolizing enzymes. J Nutr. 2004 Oct;134(10 Suppl):2815S-2820S.
47. Ip C, Birringer M, Block E, et al. Technology and application of selenium to cancer prevention. Nutr Cancer. 2000;36(1):6-12.
48. Yu-Chi Chen, K. Sandeep Prabhu, Andrea M. Mastro. Is Selenium a Potential Treatment for Cancer Metastasis? Nutrients. 2013;5:1149-1168.
49. Wrobel JK, Seelbach MJ, Chen L, Power RF, Toborek M. Supplementation with selenium-enriched yeast attenuates brain metastatic growth. Nutr Cancer. 2013;65(4):563-70.
50. Bhattacharjee A, Basu A, Ghosh P, et al. Protective effect of Selenium nanoparticle against cyclophosphamide induced hepatotoxicity and genotoxicity in Swiss albino mice. J Biomater Appl. 2014 Feb 12.
51. de Miranda JX, Andrade FD, Conti AD, et al. Effects of selenium compounds on proliferation and epigenetic marks of breast cancer cells. J Trace Elem Med Biol. 2014 Jul 16.
52. Babaknejad N, Sayehmiri F, Sayehmiri K, et al. The relationship between selenium levels and breast cancer: a systematic review and meta-analysis. Biol Trace Elem Res. 2014 Jun;159(1-3):1-7.
53. Kahya MC, Nazıroğlu M, Çiğ B. Selenium reduces mobile phone (900 MHz)-induced oxidative stress, mitochondrial function, and apoptosis in breast cancer cells. Biol Trace Elem Res. 2014 Aug;160(2):285-93.
54. Wesolowski LT, Semanchik PL, White-Springer SH. Beyond antioxidants: Selenium and skeletal muscle mitochondria. Front Vet Sci. 2022 Dec 1;9:1011159.
55. Cai Z, Zhang J, Li H. Selenium, aging and aging-related diseases. Aging Clin Exp Res. 2019 Aug;31(8):1035-1047.
56. Alehagen U, Opstad TB, Alexander J, et al. Impact of Selenium on Biomarkers and Clinical Aspects Related to Ageing. A Review. Biomolecules. 2021 Oct 7;11(10):1478.
57. Gu WJ, Huang W, Zhao FZ, et al. Selenium nanoparticles as adjunctive therapy in sepsis: A pilot randomized clinical trial. Drug Resist Update. 2026 May;86:101389.